[NMusers] Pred Exit Error =1 with $SIM

I am running a simulation with subproblems = 1000. One of the replicates generates the following error: PROBLEM NO.: 1 SUBPROBLEM NO.:160 0PRED EXIT CODE = 1 0INDIVIDUAL NO. 79 ID=0.13034000E+04 (WITHIN-INDIVIDUAL) DATA REC NO. 2

[NMusers] General question on modeling

ssion model. Pete bonate Peter Bonate, PhD, FCP -Original Message- From: [EMAIL PROTECTED] <[EMAIL PROTECTED]> To: 'Mark Sale - Next Level Solutions' <[EMAIL PROTECTED]> CC: nmusers@globomaxnm.com Sent: Mon Mar 19 19:42:18 2007 Subject: RE: [NMusers] General questi

Re: [NMusers] General question on modeling

eral question on modeling > From: "Bonate, Peter" <[EMAIL PROTECTED]> > Date: Tue, March 20, 2007 8:20 am > To: > > Sometimes these threads kill me. There is a degree of art to modeling. > The art is the intangible things that we do during model developmen

[NMusers] input conversion error

FOR DATA: (E7.0,E10.0,E3.0,E5.0,E7.0,E2.0,E5.0,2E2.0,E9.0,E7.0,2E6.0,5E9.0) Does anyone know what this error means and how to correct it? thanks, pete bonate Peter L. Bonate, PhD, FCP Time Magazine Person of the Year for 2006 Genzyme Corporation Senior Director, Pharmacokinetics 4545

[NMusers] Windows Vista

Before I get started I thought I would ask whether anyone knew of any issues regarding running or installing NM V or VI under Windows Vista? Thanks, pete bonate Peter L. Bonate, PhD, FCP Genzyme Corporation Senior Director, Pharmacokinetics 4545 Horizon Hill Blvd San Antonio, TX 78229 USA

RE: [NMusers] Windows Vista

dows XP Diane ________ From: [EMAIL PROTECTED] [mailto:[EMAIL PROTECTED] On Behalf Of Bonate, Peter Sent: Thursday, May 10, 2007 9:47 AM To: nmusers@globomaxnm.com Subject: [NMusers] Windows Vista Before I get started I thought I would ask whether anyone knew

[NMusers] mid-infusion higher than end of infusion

any real value any longer. Any opinions on the validity of throwing out the data, just running with the model that ignores the phenomenon and has high residual variability, or something else I haven't been able to think of would be appreciated. Thanks, pete bonate Peter L. Bonate, PhD

[NMusers] sample size issue

population mean clearance was less than 30% CV. Does anyone know how to do this a priori? Does this seem to be something new? Thanks, pete bonate Peter L. Bonate, PhD, FCP Genzyme Corporation Senior Director, Pharmacokinetics 4545 Horizon Hill Blvd San Antonio, TX 78229 USA [EMAIL PROTECTED

RE: [NMusers] RE: re: bug in NONMEM VI?

I'd also like to see how correlated COV3 and COV4 are. This may be a collinearity issue. pete bonate Peter L. Bonate, PhD, FCP Genzyme Corporation Senior Director Clinical Pharmacology and Pharmacokinetics 4545 Horizon Hill Blvd San Antonio, TX 78229 USA [EMAIL PROTECTED] phone: 21

RE: Antwort: [NMusers] PK/PD models to describe anti-ancer drug effect on the tumor volume

uld expect that your IC50s would be similar regardless of whether you model mean data or individual-level data. Hope this helps pete bonate Peter L. Bonate, PhD, FCP Genzyme Corporation Senior Director Clinical Pharmacology and Pharmacokinetics 4545 Horizon Hill Blvd San Antonio, TX 78229 USA [E

RE: [NMusers] "Connect the dots" approach for a time-varying covariate

values as predictors in the imputation process. pete bonate Peter L. Bonate, PhD, FCP Genzyme Corporation Senior Director Clinical Pharmacology and Pharmacokinetics 4545 Horizon Hill Blvd San Antonio, TX 78229 USA [EMAIL PROTECTED] phone: 210-949-8662 fax: 210-949-8219 crackberry: 210-315-2713

[NMusers] Outstanding Paper in Modeling and Simulation

The Clinical Pharmacology and Translational Research (CPTR) Section within AAPS wishes to announce a new award to be presented at the AAPS Annual Meeting - Outstanding Manuscript in Modeling and Simulation. The review committee is currently soliciting nominations for the award. The scientific impa

[NMusers] CrcL or Cr in pediatric model

there might be collinearity issues with CrCL and weight in the same model, even though they are both significant. Does anyone have a good argument for using CrCL in the model instead of serum Cr? Thanks Pete bonate Peter L. Bonate, PhD, FCP Genzyme Corporation Senior Director Clinical P

nmusers@globomaxnm.com

Every year the Clinical Pharmacology and Translational Research Section within AAPS recognizes an Outstanding Manuscript in Modeling and Simulation that advances clinical pharmacology or translational research through the use of modeling and simulation. Last year's winner was Kaori Ito, Matt Hutm

[NMusers] Quinidine dataset

Does anyone have the infamous Quinidine dataset from Verme et al. that they can share with me. Any format would be acceptable. Thanks pete Peter L. Bonate, PhD, FCP Genzyme Corporation Senior Director Clinical Pharmacology and Pharmacokinetics 4545 Horizon Hill Blvd San Antonio, TX 78229 US

[NMusers] Pharmacoeconomic simulations

Is anyone aware of any papers or abstracts using computer-assisted trial design that incorporates a pharmacoeconomic component to the simulation? Or any pop pharmacokinetic-pharmacodynamic papers that include the same? Thanks Pete bonate Peter L. Bonate, PhD, FCP Genzyme Corporation Senior

[NMusers] Open Position for PKMS Modeler at Astellas

Dear Friends, Astellas is a bright spot in the pharmaceutical industry, not just because of what we do, but in the way we do it. At a time when many pharmaceutical companies are down-sizing, Astellas is growing. If you are looking for a company where you can change a life, make a dream come tr

[NMusers] help on problem with baseline estimation

1.1656E+02 1.1433E+02 0.E+00 0.E+00 0.E+00 The baseline is 117.7 but DELTA has values of 116.6. I cannot figure out what NONMEM is doing. Can anyone offer any suggestions. Thanks, pete bonate Peter L. Bonate, PhD Senior Director Global Head - Pharmacokinetics, Modeling, and

RE: [NMusers] Problem in Simulation

The problem looks like this part of the code: ((CIRC0/A(5))**GAM Either CIRCO0 or A(5) is equal to zero. Try this ((CIRC0/A(5) + .01)**GAM pete Peter L. Bonate, PhD Senior Director Global Head - Pharmacokinetics, Modeling, and Simulation Global Clinical Pharmacology & Exploratory Develop

[NMusers] Contributors needed for Themed Issue of Journal of PKPD

m and ask them to contact me. Thanks, Pete Bonate Peter L. Bonate, PhD Senior Director Global Head - Pharmacokinetics, Modeling, and Simulation Global Clinical Pharmacology & Exploratory Development Astellas 1 Astellas Way, 2N.184 Northbrook, Il 60062 phone: 224-205-5855 fax: 224-205-5

RE: [NMusers] Minimization Terminated in Bootstrapping

Not just yet. I’ve seen many people just naively bootstrap their dataset. It may be that your bootstrap datasets do not adequately represent model development dataset. For example suppose you had 75% sparse data and 25% rich data in your model development set. It is imperative that your boot

[NMusers] Open Position at Astellas: Associate Director/Senior Manager in PKMS

Astellas is a bright spot in the pharmaceutical industry, not just because of what we do, but in the way we do it. At a time when many pharmaceutical companies are down-sizing, Astellas is growing. If you are looking for a company where you can change a life, make a dream come true, and light th

[NMusers] A new book on Model Communication

look forward to feedback to make it better in the future. Pete Bonate Peter L. Bonate, PhD Senior Director Global Head - Pharmacokinetics, Modeling, and Simulation Global Clinical Pharmacology & Exploratory Development Astellas 1 Astellas Way, 2N.184 Northbrook, Il 60062 phone: 224-205

[NMusers] RE: tracer-tracee kinetics

Ann There is a great book on this by David Foster. It is sold on Amazon but is kind of expensive. http://www.amazon.com/Tracer-Kinetics-Biomedical-Research-Model/dp/0306464276 I think this could be an invaluable resource for you. pete Peter L. Bonate, PhD Executive Director Global Head - Ph

Re: [NMusers] RE: Estimation of ke0 from raw data

Ken Kowalski published a paper many years ago which I think he called a semicompartmental method. It was not developed as a population approach and only applies to single dose data but works really well under those conditions. It was published in the Journal of Pharmacokinetics and Biopharmace

[NMusers] Themed issue on Recent

The Journal of Pharmacokinetics and Pharmacodynamics is soliciting articles for a themed issue on Recent Advances in Cardiovascular Pharmacokinetic-Pharmacodynamic modeling. Articles must be submitted by 15 October 2017 for a planned publication date of January 2018. Articles must be 4000-800

Re: [NMusers] Why should we avoid using micro rate constants?

You may have found a local minima with the microconstant parameterization. There generally isn’t any rhyme or reason for why one chooses macro or micro constants. People will argue that the macro model with Q and Vp is more interpretable than k12 and k21. That, and scaling reasons, are why one

[NMusers] Summer Internship Available at Astellas

Summer Internship at Clinical Pharmacology & Exploratory Development (CPED), Astellas Pharma Global Development, Inc. Northbrook, IL Job Title: Astellas CPED Summer Research Intern Number of Positions: 1 Type of Student: PhD candidate in pharmacometrics, biomedical engineering Deadline for Apply

[NMusers] Post-Doctoral Fellowship in Artificial Intelligence in Clinical Pharmacology at Astellas

Post-Doctoral Fellowship in Artificial Intelligence in Clinical Pharmacology at Astellas The Pharmacometrics group in the Clinical Pharmacology and Exploratory Development (CPED) Department at Astellas has an immediate opening for a full-time, 1-year (with optional 2nd year) post-doctoral fellow

RE: [NMusers] AMD vs Intel

Leonid - when you say different. What do you mean? Fixed effect and random effects? Different OFV? We did a poster at AAPS a decade or so ago comparing results across different platforms using the same data and model. We got different results on the standard errors (which related to matrix

[NMusers] Post-Doctoral Fellowship in Artificial Intelligence in Clinical Pharmacology at Astellas

Post-Doctoral Fellowship in Artificial Intelligence in Clinical Pharmacology at Astellas The Pharmacometrics group in the Clinical Pharmacology and Exploratory Development (CPED) Department at Astellas has an immediate opening for a full-time, 1-year (with optional 2nd year) post-doctoral fellow

RE: [NMusers] Assessment of elimination half life of mAb

I've never really been happy with this. It's an unsatisfactory solution. You have a nonlinear drug. Let's assume you have an approved drug. It's given at some fixed dose. The clinician wants to know what is the drug's half-life so they can washout their patient and start them on some other

RE: [NMusers] Assessment of elimination half life of mAb

: Justin Wilkins ; Bill Denney ; Bonate, Peter ; Niurys.CS Cc: nmusers@globomaxnm.com Subject: Re: [NMusers] Assessment of elimination half life of mAb still, half-life of the linear part could be helpful in cases when non-linearity plays no significant role in elimination, so we tend to present

[NMusers] Pharmacometrics or QSP summer internship at Astellas US in 2021

A full-time, paid internship in Pharmacometrics or Quantitative Systems Pharmacology is available at Astellas in the summer of 2022 for approximately 12 weeks. The intern will work closely with a senior-level pharmacometrician on topics related to mechanistic modeling or pharmacometrics, dependi

RE: [NMusers] flip-flop without absorption information?

In comment to Shan’s statement: It's my understanding that this flip-flop phenomenon is fundamentally a mathematical problem -- that is, if we write down a PK model in its analytical form, it becomes rather easy to understand that swapping the values between ka and ke (CL/V) would lead to the s

RE: [NMusers] Condition number

This is also discussed in my book on page 70. The first definition is simply the ratio of the largest to smallest eigenvalue K = L1/Lp (51) where L1 and Lp are the largest and smallest eigenvalues of the correlation matrix (Jackson 1991). The second way is to define K as K = sqrt(L1/Lp)(5

Re: [NMusers] Condition number

This is great. Just like the glory days of NMusers. Any moment now Nick Holford is jointing to chime in. I’m not an expert in matrix algebra but is the correlation matrix the right one to be using? We are concerned about inversion of the hessian. That instability is what affects our paramete

RE: [NMusers] Condition number

“Dancing with the Stars” is not owned by Astellas. -Original Message- From: Ken Kowalski Sent: Tuesday, November 29, 2022 8:29 PM To: Bonate, Peter ; 'Leonid Gibiansky' Cc: 'Matthew Fidler' ; 'Kyun-Seop Bae' ; nmusers@globomaxnm.com; 'Jeroen Elassaiss-Scha

RE: [NMusers] Condition number

Simulation (PKMS) Clinical Pharmacology and Exploratory Development (CPED) Astellas 1 Astellas Way Northbrook, IL 60062 peter.bon...@astellas.com (224) 619-4901 Quote of the week – “Dancing with the Stars” is not owned by Astellas. -Original Message- From: Bonate, Peter Sent

[NMusers] Pharmacometrics summer internship at Astellas US

A full-time, paid internship in pharmacometrics is available at Astellas in the summer of 2024 for approximately 12 weeks. Successful candidates will work closely with a senior-level pharmacometrician on topics related to population pharmacokinetics or pharmacometric methods, depending on the in

[NMusers] RE: Historical question

this started with NONMEM IV. There was a history of NONMEM webpage that Icon maintained, but when I checked today, it no longer looks like it is functional. https://nonmem.iconplc.com/nonmem_history/NONMEM_history4.pdf Pete Bonate Peter Bonate, PhD Suzerain, New Technologies Early Development